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In this issue of Value in Health, we launch a new dedicated forum
for scientiﬁc debate of unresolved questions in pharmacoeco-
nomics and outcomes research. By inviting short contributions
reﬂecting different standpoints, the Point/Counter-Point space
will provide a platform for clear and concise discussion of themes
of general interest to the journal readership. We welcome sug-
gestion for topics. We are planning to work with experts to
develop a stimulating set of debates on important topics.
The ﬁrst Point/Counter-Point of the series is titled “Economic
evaluation of medical devices and drugs—same or different?” We
have the pleasure to host contributions from Drummond et al.
and from Taylor and Iglesias [1,2].
Both papers agree on a number of points. First is the principle
that the general methods that govern the application of economic
evaluation methods can be equally applied to drugs and medical
devices. Second, there are a number of inherent characteristics
speciﬁc to the technology, which makes the assessment of the
(effectiveness and cost-effectiveness) evidence of medical devices
somewhat more challenging to assess. Third, they agree that
there is currently an asymmetry in the way in which drugs and
medical devices are regulated.
Nevertheless, because “the devil is in the detail,” the articles
also offer different elements for consideration. First is the need to
reconsider the regulatory regimens of medical devices. In their
current status, at least in Europe and North America, these
regimens provide unclear incentives to R&D, licensing, price
competition, and generation of robust clinical evidence. Second is
the need to further develop cost-effectiveness methods to account
for the issues posed by the evidence base relating to medical
devices. Heterogeneous study designs, center and learning effects,
bias in nonrandomized evidence, rapidly evolving technologies,
absence of a “class effect,” interaction between drugs and
devices, and highly dynamic price variation are only few
examples.
Perhaps the reader may want to think of whether she wishes
to address the “normative” or the “positive” nature of the ques-
tion (normative statements are concerned with describing how
things should or ought to be, how to value them, which things
are good or bad, which actions are right or wrong. Positive
statements on the other hand are descriptive or explanatory, and
in that sense are falsiﬁable statements that attempt to describe
reality). That is, one could attempt to describe the status quo
relating to the economic evaluation of drugs and medical devices.
Alternatively, one could ask whether economic evaluation of
drugs and devices should be different.
Inevitably, these questions will lead to others—such as:
Should the decision-making requirements for coverage and reim-
bursement be different for drugs and medical devices? Should the
regulatory framework be the same?
These are important issues that researchers, policymakers,
and the pharmaceutical and medical devices industry may need
to address in the future.
We hope this debate will stimulate readers to express their
views on the question at hand with their colleagues, sharing their
experiences in the ﬁeld.
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